Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients.
about
Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?Current strategies to treat tuberculosisNew anti-tuberculosis drugs and regimens: 2015 updateTuberculosis therapy for 2016 and beyond.Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines.High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.The anti-tuberculosis agents under development and the challenges ahead.Synthetic investigational new drugs for the treatment of tuberculosis.Inhibition of Leishmania mexicana Growth by the Tuberculosis Drug SQ109Improved power for TB Phase IIa trials using a model-based pharmacokinetic-pharmacodynamic approach compared with commonly used analysis methods.Targeting Energy Metabolism in Mycobacterium tuberculosis, a New Paradigm in Antimycobacterial Drug Discovery.News on therapeutic management of MDR-tuberculosis: a literature review.Extensively drug-resistant tuberculosis in India: Current evidence on diagnosis & management.Acquisition of Rifampin Resistance in Pulmonary Tuberculosis.Bioenergetics of Mycobacterium: An Emerging Landscape for Drug Discovery.The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis.Challenging the Drug-Likeness Dogma for New Drug Discovery in Tuberculosis
P2860
Q26771997-9E865495-3A87-4063-B7F0-B995E1AA24F2Q28075252-76777FF4-5A79-4A20-9D1D-0479A673E8D8Q28596775-67DFB368-F5AA-4D91-B6EF-5B689BC11D58Q30248788-3A5FEF3C-BAE1-479F-AC77-598A726B1C7BQ36094215-5E8C4B08-F8F2-483E-95B9-04D504B27AC2Q37507802-B9FEA458-CED5-4AC4-838D-EB7CC960DA6AQ38617197-FCFA2991-0E0D-4A12-BF9E-1E4139C8F400Q38635790-EA570534-2C54-4BB9-B797-6434D2C71258Q38755807-0A6C3C4D-9E96-43E8-9104-7C4DD3912CD5Q38777021-544CD09C-BA60-4CF3-A380-F3D4BCB276C9Q39235946-2A405705-0EA8-4D28-AF35-8F3E0CA9CE12Q39398924-2DFB66D9-D163-4559-B8F5-845E000422D5Q41376759-91A67452-A72F-4517-9ADD-E5D5CB3DDA5AQ41695565-EA6CDF8D-247E-41A7-B412-2B31B76D175EQ52688603-89762E14-8BF9-4CD4-B8F0-9CC9FC22E06CQ55232003-C90A2C90-66AA-45CB-BF47-620773E342A4Q57656314-7D9DC3F7-03CC-4431-B3D4-6C2EE2B2C051
P2860
Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Early phase evaluation of SQ10 ...... icin in pulmonary TB patients.
@en
Early phase evaluation of SQ10 ...... icin in pulmonary TB patients.
@nl
type
label
Early phase evaluation of SQ10 ...... icin in pulmonary TB patients.
@en
Early phase evaluation of SQ10 ...... icin in pulmonary TB patients.
@nl
prefLabel
Early phase evaluation of SQ10 ...... icin in pulmonary TB patients.
@en
Early phase evaluation of SQ10 ...... icin in pulmonary TB patients.
@nl
P2093
P2860
P50
P356
P1476
Early phase evaluation of SQ10 ...... icin in pulmonary TB patients.
@en
P2093
Amour Venter
Andrea Rachow
Andreas H Diacon
Andrew J Phipps
Carol A Nacy
Gary Horwith
Jeannine du Bois
Kim Narunsky
Martin J Boeree
Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA)
P2860
P304
P356
10.1093/JAC/DKU553
P407
P577
2015-01-27T00:00:00Z